Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 653.60M | 1.10B | 1.03B | 1.19B | 1.08B |
| Total Depreciation and Amortization | 69.20M | 56.50M | 55.90M | 24.50M | 54.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | 31.20M | -- |
| Total Other Non-Cash Items | 60.80M | 84.10M | 96.10M | 199.00M | -45.10M |
| Change in Net Operating Assets | -140.50M | -115.00M | 244.70M | -947.80M | 149.60M |
| Cash from Operations | 643.10M | 1.13B | 1.43B | 498.00M | 1.24B |
| Capital Expenditure | -97.30M | -112.20M | -133.40M | -149.40M | -101.80M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -9.06B | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.06B | 66.40M | -298.50M | -138.70M | -15.20M |
| Cash from Investing | -6.10B | -45.80M | -431.90M | -288.10M | -117.00M |
| Total Debt Issued | 4.50B | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -1.40M | -- |
| Issuance of Common Stock | 22.90M | 47.70M | 27.00M | 54.00M | 7.90M |
| Repurchase of Common Stock | -206.00M | -473.80M | -565.40M | -130.90M | -1.16B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.80M | -600.00K | -400.00K | 1.10M | -300.00K |
| Cash from Financing | 4.30B | -426.70M | -538.80M | -77.20M | -1.15B |
| Foreign Exchange rate Adjustments | -4.90M | -3.70M | -40.30M | 7.30M | -4.10M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.17B | 649.20M | 417.10M | 140.00M | -34.20M |